Caribou Biosciences to Participate in Upcoming Investor Conferences

BERKELEY, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following investor conferences:

• Citi 17^th Annual BioPharma Conference, Boston
  
  Panel participation on September 8, 2022, 11:20 am ET
  
  

• H.C. Wainwright 24^th Annual Global Investment Conference, New York City
  
  Corporate presentation on September 13, 2022, 10:00 am ET
  
  

• Morgan Stanley 20^th Annual Global Healthcare Conference, New York City
  
  Fireside chat on September 13, 2022, 4:40 pm ET
  
  

• Jefferies Cell and Genetic Medicines Summit, New York City
  
  September 29-30, 2022; see page for details

For more information, visit the page on Caribou’s website. Webcasts will be available on the Caribou website for 30 days after the event.

About Caribou’s Novel Next-Generation CRISPR Platform

CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays”) that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA technology to carry out high efficiency multiple edits, including multiplex gene insertions, to develop CRISPR-edited therapies.

About Caribou Biosciences, Inc.

Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its proprietary Cas12a chRDNA technology, enables superior precision to develop cell therapies that are specifically engineered for enhanced persistence. Caribou is advancing a pipeline of off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of patients with hematologic malignancies and solid tumors.

For more information about Caribou, visit and follow the company @CaribouBio.

“Caribou Biosciences” and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.

Caribou Biosciences, Inc. Contacts:

Investors:

Amy Figueroa, CFA

Media:

Peggy Vorwald, Ph.D.

Investors and Media:

Elizabeth Wolffe, Ph.D., and Sylvia Wheeler

Wheelhouse LSA